Close

Adamas Pharma (ADMS) Presents Statistically Significant ADS-5102 Phase 3 Data in PD Associated LID

April 20, 2016 6:37 AM EDT Send to a Friend
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced positive findings from its lead Phase 3 study (EASE LID) evaluating ADS-5102 (amantadine HCl) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login